Learn More
BACKGROUND To evaluate the safety and immunogenicity of a new inactivated hepatitis A virus (HAV) vaccine. METHODS In a randomized controlled trail thirty-one HAV-seronegative adults were enrolled and randomly assigned to either study group or control group. Subjects in the study group were given 1000 units of the new inactivated HAV vaccine, with a(More)
  • 1